 | | Vol. 12.21 – 1 June, 2021 |
| |
|
|
| The authors found that YTHDC1 was the essential N6-Methyladenosine (m6A) reader in myeloid leukemia from a genome-wide CRISPR screen and that m6A was required for the formation of a nuclear body mediated by phase separation that maintained mRNA stability and controlled cancer cell survival and differentiation.
[Cancer Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators utilized various methods to understand the effects of age-regulated systemic factors on HSCs and their bone marrow niche.
[Journal of Experimental Medicine] |
|
|
|
| Scientists developed a flow cytometry-based assay for evaluation and monitoring of epichaperome abundance at the single-cell level, with the goal of prospectively identifying patients likely to respond to epichaperome inhibitors.
[npj Precision Oncology] |
|
|
|
| Researchers demonstrated critical but unanticipated functions of mitochondria during the erythroblast enucleation process, relevant to the in vitro production of red blood cells as well as to disorders of the erythroid lineage.
[Blood Advances] |
|
|
|
| Investigators identified evidence to support the specificity of lipogenesis pathways, suggested a potential basis of how perturbation of these pathways may interact synergistically to promote myeloid differentiation, and offered potential drug combination strategies in the treatment of acute myeloid leukemia.
[iScience] |
|
|
|
| Scientists substituted the hydroxyl group in hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, with a triphenylphosphonium cation attached to an alkyl group with different chain lengths, forming a new class of mitochondria-targeted HU.
[iScience] |
|
|
|
| Researchers demonstrated that DNA methyltransferase 3A (DNMT3AR882H)-dependent clonal hematopoiesis and acute myeloid leukemia cells were specifically susceptible to the hypomethylating agent azacytidine.
[Nature Cancer] |
| |
|
|
| This Phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in newly diagnosed patients with acute myeloid leukemia (AML) and relapsed or refractory AML.
[Journal of Clinical Oncology] |
|
|
|
| Part B of this Phase Ib study evaluated the safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients.
[Leukemia] |
|
|
|
|
| The authors present all the approved drugs as well as important drug candidates in clinical trials for various target classifications, discuss the current challenges, and provide insights and perspectives for the research and development of anti-cancer drugs.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators discuss some of the challenges related to the current myelodysplastic syndromes treatment landscape, as well as new approaches currently in development.
[Leukemia] |
|
|
|
| Scientists discuss recent progress in the erythroid culture field as well as opportunities for further scaling up of manufactured red blood cell production for transfusion practice.
[Haematologica] |
|
|
|
|
| GlycoMimetics, Inc. announced that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigator-sponsored trial evaluating uproleselan as a prophylactic agent to reduce gastrointestinal toxicities associated with high-dose melphalan in autologous hematopoietic cell transplantation for multiple myeloma.
[GlycoMimetics, Inc.] |
|
|
|
| Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for chronic granulomatous disease.
[Jasper Therapeutics, Inc. (Business Wire, Inc.)] |
|
|
|
|
| August 18 – 19, 2021
Virtual |
|
|
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | The University of Edinburgh – Edinburgh, Scotland, United Kingdom |
|
|
|
| | University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Technische Universität Dresden – Dresden, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
